Akums Pharma Appoints Amrut Medhekar as CDMO CEO

Before joining Akums, Medhekar was President of India Business at Wockhardt, leading significant growth initiatives.

Akums Drugs and Pharmaceuticals has appointed Amrut Medhekar as Chief Executive Officer of its Contract Development and Manufacturing Organization (CDMO) business, effective August 24, 2024.

Medhekar, who will report to Joint Managing Directors Sanjeev Jain and Sandeep Jain, brings over 27 years of experience in the pharmaceutical industry, with expertise in corporate strategy, business leadership, key account management, portfolio strategy, and supply management.

Before joining Akums, Medhekar was President of India Business at Wockhardt, leading significant growth initiatives.

His career also includes notable positions at Zydus Group, Novartis, JK Tyre and Industries, Life Medicare Biotech, Torrent Pharma, and Ranbaxy.

Medhekar has also contributed to academia, serving as a jury member for the HULT Prize $1M Challenge at IIM Ahmedabad and as a speaker at various management institutes, including FMS, Symbiosis, AIMA, and UpGrad.

Recent Appointments in the Healthcare Space

In June, Gland Pharma named Srinivas Sadu, the incumbent MD and CEO, as the executive chairman and CEO of the company, effective June 10, 2024.

A seasoned professional with over two decades of extensive experience, Sadu has played a pivotal role in Gland's journey. He assumed the position of MD and CEO on April 25, 2019, and has been instrumental in driving the company's growth and success.

Days back, Mumbai-based Medikabazaar, a leading B2B e-commerce platform for medical supplies, appointed Dinesh Lodha as its new Group Chief Executive Officer (CEO).

Lodha’s appointment comes at a pivotal time as Medikabazaar seeks to expand its footprint both domestically and internationally amidst a rapidly growing healthcare market. Dinesh Lodha joins Medikabazaar with over 20 years of experience in the medtech sector, having held leadership roles across various industries, including FMCG, healthcare, and medical consumables.

Likewise, Paras Health appointed Usha Rajeev as an Independent Director. Rajeev brings experience from her previous role at Price Waterhouse, India, a member firm of Price Waterhouse Coopers (PwC) International, where she served as a Partner for over 19 years until her retirement in 2018.

Her extensive background in governance, audit, and risk management is expected to enhance the board's oversight capabilities and support Paras Health's strategic objectives.